2927 AFC HD AMS Life Science
- 854
- -8-0.93%
AFC HD AMS Life Science News
J-Front, 24/2 operating profit up 125.9% to 43 billion yen, 25/2 forecast down 12.9% to 37.5 billion yen
The financial results for the fiscal year ending 2024/2 announced by J-Front ＜3086＞ were sales revenue of 407.0.06 billion yen, up 13.2% from the previous fiscal year, and operating profit of 43,048 billion yen, up 125.9% from the same period. Although the effects of the COVID-19 infection have been prolonged, major management numerical targets, including consolidated operating profit targets set in the mid-term plan, were generally achieved, and the financial position was improved by reducing interest-bearing debt, etc. As for the fiscal year ending 2025/2, sales revenue increased 3.6% from the previous fiscal year to 421.5 billion yen, and operating profit decreased 12.9%
AFC HD AMS Life Science 1H Net Y641.00M Vs Net Y414.00M
AFC-HD AMS Life Science Co. Ltd. (2927.TO) Japan 1st Half Ended February 29 GROUP 2024 2023 Revenue Y14.54 bln Y12.44 bln Operating Profit
J front, TKP, Shochiku, Toho (15 days)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------4/15 (Mon) ＜135A＞VRAIN ＜1887＞Japan Land Development ＜2292＞S Foods ＜2337＞Ichigo ＜2338＞Quantum S ＜2404＞Tetsujin HD ＜2484＞Delivery Hall ＜2884＞Yoshimuraf
Chiyo Kaken, etc. [Myomi brands seen from changes in turnover]
Stock closing price turnover compared to the previous day*＜6579＞Logley 546 8 321100*＜7919＞Nozaki Seal 164 5 1501900*＜5724＞Asaka Riken 1095 55 256600*＜5133＞Terilogy HD 301 2 965400*＜3779＞J-SCOM HD 150 8 1712500*＜2927＞AFC
Merchant, Rohm, Manny, etc
Significant continued growth. An upward revision of the first half earnings forecast was announced the day before. Operating profit was raised from the previous forecast of 770 million yen to 1.02 billion yen, up 50.9% from the same period last year.
AFC-HD is ranked and the first half earnings forecast is revised upward
AFC-HD ＜2927＞ is in the ranking (as of 9:32). Significant continuous growth. After the transaction ended the day before, the first half earnings forecast was revised upward, and it seems to be a source of buyers. Operating profit is expected to be 1,023 million yen (up 50.8% from the same period last year). That's up about 32% from the previous forecast. The domestic healthcare business and pharmaceutical business remained steady. The full-year forecast has not been revised. Operating profit for the fiscal year ending 2014/8 is expected to be 1,801 billion yen (up 10.1% from the previous fiscal year). Turnover rate increase
4/9 [Today's Investment Strategy]
[FISCO Specially Selected Brand] [Material Brand] AFC-HD Ams Life Science ＜2927＞ 913 yen (4/8) health food contract manufacturing (OEM) manufacturer. Earnings forecasts for the first half have been revised upward. Operating profit is expected to be 1,023 million yen (up 50.8% from the same period last year). That's up about 32% from the previous forecast. The domestic healthcare business and pharmaceutical business remained steady. Also, Saikaya, which is responsible for the department store business, turned into a surplus. The full-year forecast has not been revised. Operating profit for the fiscal year ended '8/24
Pay attention to Create SD and Euglena, are Iida GHD and ROHM doing soft
On the US stock market yesterday 8th, the NY Dow depreciated by 11.24 dollars to 38,892.80, the Nasdaq Composite Index was 5.44 points higher at 16,253.96, and the Chicago Nikkei 225 futures were 39450 yen, 60 yen higher than the Osaka Japan-China ratio. The exchange rate is 1 dollar = 151.70-80 yen. In today's Tokyo market, eBase ＜3835＞, which revised the earnings forecast for the fiscal year ending March 31, '24 upward, and CREATE SD (3148), which revised the earnings forecast for the fiscal year ending 24/5 upward, raised the dividend payout ratio from 30% to 35%
In the midst of a stalemate, individual response using settlement as a clue
[Stock Opening Comment] The Japanese stock market on the 9th is likely to have a strong sense of stalemate. In the US market on the 8th, the NY Dow depreciated by 11 dollars and the NASDAQ was 5 points higher. Purchases continued after the previous weekend's March US employment statistics, and began rising. However, in addition to rising interest rates becoming a burden, the mood to determine the results intensified as they refrained from announcing important inflation indicators such as the consumer price index (CPI) scheduled to be announced this week. Chicago Nikkei 2
Fuji's 24/2 operating profit increased 33.5% to 15.1 billion yen, 25/2 forecast 2.6% increase 15.5 billion yen
As for the financial results for the fiscal year ending 2024/2 announced by Fuji ＜8278＞, operating revenue was 801,022 billion yen, up 2% from the previous fiscal year, and operating profit was 15.110 billion yen, up 33.5% from the same period. The earnings forecast was revised upward on the 3rd, and it landed in line with this. In addition to cost reduction effects etc. by creating integrated synergy effects, we worked to improve productivity by utilizing process centers and promoting digitalization. The financial results for the fiscal year ending 2025/2 were 810 billion yen, up 1.1% from the previous fiscal year, and sales
AFC HD AMS Life Science Sees 1H Parent Pretax Y1.06B
PARENT New Forecast Prior For Year to Feb 2024 Forecast Revenue Y14.66 bln N/A Pretax Profit Y1.06 bln N/A Net Prof
AFC HD AMS Life Science 1Q Net Y318.00M Vs Net Y160.00M
AFC-HD AMS Life Science Co. Ltd. (2927.TO) Japan 1st Quarter Ended November 30 GROUP 2023 2022 Revenue Y6.79 bln Y5.69 bln Operating Profi
AFC HD AMS Life Science FY Net Y1.10B Vs Net Y735.00M
AFC-HD AMS Life Science Co. Ltd. (2927.TO) Japan Year Ended August 31 GROUP 2023 2022 Revenue Y25.58 bln Y23.02 bln Operating Profit Y1.64
AFC HD AMS Life Science Sees FY Net Y1.12B
AFC-HD AMS Life Science Co. Ltd. also released the following forecasts: GROUP 1st Half To Year Ending Feb 2024 Aug 2024 Revenue Y13.76 bln
AFC HD AMS Life Science Sees FY Net Y983.00M
AFC-HD AMS Life Science Co. Ltd. also released the following forecasts: GROUP Year Ending Aug 2023 Revenue Y25.04 bln Operating Profit Y1.56 bln
AFC HD AMS Life Science Raises FY Net View to Y860.00M
GROUP New Forecast Prior For Year To Aug 2023 Forecast Revenue Y24.74 bln Y24.74 bln Operating Profit Y1.48 bln
AFC HD AMS Life Science 1H Net Y414.00M Vs Net Y307.00M
AFC-HD AMS Life Science Co. Ltd. (2927.TO) Japan 1st Half Ended February 28 GROUP 2023 2022 Revenue Y12.44 bln Y11.20 bln Operating Pr
AFC HD AMS Life Science Sees 1H Parent Pretax Y662.00M
PARENT New Forecast Prior For Year to Feb 2023 Forecast Revenue Y12.19 bln N/A Pretax Profit Y662.00 mln N/A Net
AFC HD AMS Life Science Raises FY Dividend Plan to Y27.50
AFC-HD AMS Life Science Co. Ltd. (2927.TO) PARENT Latest Revision Previous For Year to Aug 2023 Plan Midyear Y12.50 Y12.50 Year-end Y15.00
AFC HD AMS Life Science 1Q Net Y160.00M Vs Net Y156.00M
AFC-HD AMS Life Science Co. Ltd. (2927.TO) Japan 1st Quarter Ended November 30 GROUP 2022 2021 Revenue Y5.69 bln Y5.46 bln Operating
Analysis
Price Target
No Data
